康力欣胶囊联合FOLFOX4方案对中晚期胃癌患者免疫功能、生活质量和血清肿瘤标志物的影响.

Autor: 李鹏远^1,2 lpy524627@163.com, 王晓芳¹, 刘月¹, 张慧英¹, 张清华¹, 张丽娇³

Publikováno v: Progress in Modern Biomedicine. 2022, Vol. 22 Issue 1, p73-77. 5p.

Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study

Autor: Juxian Sun, Feifei Mao, Chang Liu, Fan Zhang, Dafeng Jiang, Weixing Guo, Lei Huo, Liping Zhou, Wan Yee Lau, Jie Shi, Shuqun Cheng

Publikováno v: Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-10 (2023)

Abstract The majority of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage. Currently, there are only a few therapeutic methods available for patients with advanced HCC and extrahepatic metastasis (EHM). Systemic chemotherapy, s

Externí odkaz: https://doaj.org/article/2492d7997a764b0aa2715dddc75560a7

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Autor: Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zou J

Publikováno v: Drug Design, Development and Therapy, Vol Volume 15, Pp 1873-1882 (2021)

Hui Li,1,* Shukui Qin,1,* Ying Liu,2 Zhendong Chen,3 Zhenggang Ren,4 Jianping Xiong,5 Zhiqiang Meng,6 Xiao Zhang,7 Linna Wang,7 Xiaojing Zhang,7 Jianjun Zou7 1Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chin

Externí odkaz: https://doaj.org/article/4b4f47ee4c1e48d293b837ca4c60c7d8

Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care.

Autor: Ying H; Department of General Surgery, Yongkang First People's Hospital, Yongkang 321300, Zhejiang Province, China., Huang RJ; Department of General Surgery, Yongkang First People's Hospital, Yongkang 321300, Zhejiang Province, China. 13758992301@163.com., Jing XM; Department of Oncology, Yongkang First People's Hospital, Yongkang 321300, Zhejiang Province, China., Li Y; Department of Oncology, Yongkang First People's Hospital, Yongkang 321300, Zhejiang Province, China., Tong QQ; Department of Oncology, Yongkang First People's Hospital, Yongkang 321300, Zhejiang Province, China.

Publikováno v: World journal of clinical cases [World J Clin Cases] 2024 Jun 26; Vol. 12 (18), pp. 3360-3367.